226 related articles for article (PubMed ID: 31048499)
21. The Ashitaba (
Zhang T; Wang Q; Fredimoses M; Gao G; Wang K; Chen H; Wang T; Oi N; Zykova TA; Reddy K; Yao K; Ma W; Chang X; Lee MH; Rathore MG; Bode AM; Ashida H; Lippman SM; Dong Z
Cancer Prev Res (Phila); 2018 Oct; 11(10):607-620. PubMed ID: 29980517
[TBL] [Abstract][Full Text] [Related]
22. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Niessner H; Schmitz J; Tabatabai G; Schmid AM; Calaminus C; Sinnberg T; Weide B; Eigentler TK; Garbe C; Schittek B; Quintanilla-Fend L; Bender B; Mai M; Praetorius C; Beissert S; Schackert G; Muders MH; Meinhardt M; Baretton GB; Dummer R; Flaherty K; Pichler BJ; Kulms D; Westphal D; Meier F
Clin Cancer Res; 2016 Dec; 22(23):5818-5828. PubMed ID: 27307593
[TBL] [Abstract][Full Text] [Related]
23. A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.
Conde-Perez A; Gros G; Longvert C; Pedersen M; Petit V; Aktary Z; Viros A; Gesbert F; Delmas V; Rambow F; Bastian BC; Campbell AD; Colombo S; Puig I; Bellacosa A; Sansom O; Marais R; Van Kempen LC; Larue L
Nat Commun; 2015 Aug; 6():8093. PubMed ID: 26307673
[TBL] [Abstract][Full Text] [Related]
24. Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.
Thang ND; Yajima I; Kumasaka MY; Iida M; Suzuki T; Kato M
Oncotarget; 2015 Jun; 6(16):14290-9. PubMed ID: 26033450
[TBL] [Abstract][Full Text] [Related]
25. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
26. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Emmons MF; Faião-Flores F; Sharma R; Thapa R; Messina JL; Becker JC; Schadendorf D; Seto E; Sondak VK; Koomen JM; Chen YA; Lau EK; Wan L; Licht JD; Smalley KSM
Cancer Res; 2019 Jun; 79(11):2947-2961. PubMed ID: 30987999
[TBL] [Abstract][Full Text] [Related]
27. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
28. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
[TBL] [Abstract][Full Text] [Related]
29. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
[TBL] [Abstract][Full Text] [Related]
30. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
[TBL] [Abstract][Full Text] [Related]
31. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail.
Hao L; Ha JR; Kuzel P; Garcia E; Persad S
Br J Dermatol; 2012 Jun; 166(6):1184-97. PubMed ID: 22332917
[TBL] [Abstract][Full Text] [Related]
32. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Paraiso KH; Das Thakur M; Fang B; Koomen JM; Fedorenko IV; John JK; Tsao H; Flaherty KT; Sondak VK; Messina JL; Pasquale EB; Villagra A; Rao UN; Kirkwood JM; Meier F; Sloot S; Gibney GT; Stuart D; Tawbi H; Smalley KS
Cancer Discov; 2015 Mar; 5(3):264-73. PubMed ID: 25542447
[TBL] [Abstract][Full Text] [Related]
33. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
34. The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis.
Grossmann AH; Yoo JH; Clancy J; Sorensen LK; Sedgwick A; Tong Z; Ostanin K; Rogers A; Grossmann KF; Tripp SR; Thomas KR; D'Souza-Schorey C; Odelberg SJ; Li DY
Sci Signal; 2013 Mar; 6(265):ra14. PubMed ID: 23462101
[TBL] [Abstract][Full Text] [Related]
35. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
36. C-Jun drives melanoma progression in PTEN wild type melanoma cells.
Kappelmann-Fenzl M; Gebhard C; Matthies AO; Kuphal S; Rehli M; Bosserhoff AK
Cell Death Dis; 2019 Aug; 10(8):584. PubMed ID: 31378787
[TBL] [Abstract][Full Text] [Related]
37. Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia.
Yasuta Y; Kaminaka R; Nagai S; Mouri S; Ishida K; Tanaka A; Zhou Y; Sakurai H; Yokoyama S
Sci Rep; 2024 Jan; 14(1):1525. PubMed ID: 38233537
[TBL] [Abstract][Full Text] [Related]
38. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
[TBL] [Abstract][Full Text] [Related]
39. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells.
Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H
J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785
[TBL] [Abstract][Full Text] [Related]
40. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]